Lymphotoxin beta receptor (LTBR)

Lymphotoxin beta receptor is a type I transmembrane protein belonging to the tumor necrosis factor (TNF) receptor superfamily. It is primarily expressed on most nonlymphoid cells—such as epithelial cells—but not on T or B lymphocytes themselves. Its main ligands are membrane-bound heterotrimers composed of lymphotoxin-alpha/beta complexes (*LTα₁β₂*) produced by activated T/B cells; it can also bind LIGHT (*TNFSF14*). Upon ligand engagement, LTBR recruits adaptor proteins TRAF2/3 leading to activation of both classical and alternative NF-kappaB signaling pathways. This results in transcriptional upregulation of genes involved in apoptosis, cytokine/chemokine production—including IL‑8—and adhesion molecules necessary for inflammation. Functionally, it plays critical roles in the development/organization of secondary lymphoid organs such as Peyer’s patches/nodes; it regulates communication between antigen-presenting cells/T-cells during adaptive immunity; it supports B-cell proliferation/differentiation indirectly through microenvironmental cues; its dysregulation has been implicated in chronic inflammatory diseases—including glomerulonephritis—and cancer progression through effects on tissue architecture/inflammatory milieu.

Other names

Tumor necrosis factor receptor superfamily member 3 (TNFRSF3)LT-beta receptorTNFCRTNFR2-RPTNF receptor-related proteinTNFR III

Drugs or biologics that block LTBR signaling typically: - Inhibit ligand binding to the receptor (e.g., blocking antibodies/fusion proteins) - Prevent downstream activation of NF-kappaB pathways, reducing pro-inflammatory cytokine/chemokine production and tissue remodeling associated with chronic inflammation or autoimmunity.